Concepedia

Lindsay Janka

LJ

Statistics

Publications

8

Citations

987

H-Index

8

Active since

2011

Affiliations

Teva Pharmaceuticals (United States)(Current)

Essen University Hospital

University of California, Los Angeles

University of Copenhagen

Thomas Jefferson University

Lindsay Janka is an author at Teva Pharmaceuticals (United States) specializing in pharmacotherapy, pharmacology, and pharmacy.

Publications per year

2011–2022

8

Publications

8

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet · 2019 · 434 citations

, , +14

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

Jonathan Corren, Steven F. Weinstein, Lindsay Janka et al. · CHEST Journal · 2016 · 383 citations

, , +15

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials

Stephen D. Silberstein, Peter McAllister, Xiaoping Ning et al. · Headache The Journal of Head and Face Pain · 2019 · 54 citations

, , +15

Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study

Messoud Ashina, Joshua M. Cohen, Maja Galić et al. · The Journal of Headache and Pain · 2021 · 43 citations · Full text

, , +15

Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Stephanie J. Nahas, Steffen Naegel, Joshua M. Cohen et al. · The Journal of Headache and Pain · 2021 · 30 citations · Full text

, , +15

1–5 of 8